ADERJANA

Brand name authorized in: Lithuania

Active ingredients

The drug ADERJANA contains a combination of these active pharmaceutical ingredients (APIs):

1 17 alpha-Ethinylestradiol
UNII 423D2T571U - ETHINYL ESTRADIOL

Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.

Read about 17 alpha-Ethinylestradiol
2 Drospirenone
UNII N295J34A25 - DROSPIRENONE

Drospirenone is a progestogen. In a therapeutic dosage, drospirenone also possesses antiandrogenic and mild antimineralocorticoid properties. It has no estrogenic, glucocorticoid and antiglucocorticoid activity. This gives drospirenone a pharmacological profile closely resembling the natural hormone progesterone.

Read about Drospirenone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Drospirenone and ethinylestradiol
G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AA Progestogens and estrogens, fixed combinations
Discover more medicines within G03AA12

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1081459, 1081460, 1081461, 1081462